Q32 Bio (QTTB) Gains from Investment Securities (2017 - 2025)
Q32 Bio's quarterly Gains from Investment Securities came in at $477000.0 in Q4 2025, up 536.0% year-on-year from $75000.0 in Q4 2024, and down 74.4% quarter-over-quarter from $1.9 million in Q3 2025.
Q32 Bio has reported Gains from Investment Securities for 9 years, with the latest figure at $477000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 536.0% year-over-year to $477000.0; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (up 6733.41% YoY), and the FY2025 full-year result was $2.2 million, changed N/A from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $477000.0, down from $1.9 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $10.0 million in Q2 2022, with the low at -$49000.0 in Q4 2022.
- Average Gains from Investment Securities over 5 years is $1.9 million, with a median of $1.1 million recorded in 2024.
- Year-over-year, Gains from Investment Securities soared 8128.57% in 2023 and plunged 98.09% in 2024.
- Tracing QTTB's Gains from Investment Securities over 5 years: stood at $303825.0 in 2021, then plunged by 116.13% to -$49000.0 in 2022, then soared by 8128.57% to $3.9 million in 2023, then sank by 98.09% to $75000.0 in 2024, then surged by 536.0% to $477000.0 in 2025.
- The last three Gains from Investment Securities figures came in at $477000.0 (Q4 2025), $1.9 million (Q3 2025), and $242813.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 477,000.00 |
| Dec 31, 2025 | 477,000.00 |
| Sep 30, 2025 | 1.86 Mn |
| Sep 30, 2025 | 1.86 Mn |
| Jun 30, 2025 | 242,813.00 |
| Jun 30, 2025 | 242,813.00 |
| Mar 31, 2025 | 65,648.00 |
| Mar 31, 2025 | 65,648.00 |
| Dec 31, 2024 | 75,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 1.07 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Dec 31, 2023 | 3.93 Mn |
| Dec 31, 2023 | 3.93 Mn |
| Sep 30, 2023 | 623,776.00 |
| Sep 30, 2023 | 623,776.00 |
| Jun 30, 2023 | 3.19 Mn |
| Jun 30, 2023 | 3.19 Mn |
| Mar 31, 2023 | 2.84 Mn |
| Mar 31, 2023 | 2.84 Mn |
| Dec 31, 2022 | -49,000.00 |
| Dec 31, 2022 | -49,000.00 |
| Sep 30, 2022 | 2.90 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 9.98 Mn |
| Jun 30, 2022 | 9.98 Mn |
| Mar 31, 2022 | 2.58 Mn |
| Mar 31, 2022 | 2.58 Mn |
| Sep 30, 2021 | 303,825.00 |
| Sep 30, 2021 | 303,825.00 |
| Jun 30, 2021 | 1.90 Mn |
| Jun 30, 2021 | 1.90 Mn |
| Mar 31, 2021 | 72,839.00 |
| Mar 31, 2021 | 72,839.00 |
| Dec 31, 2020 | -1.39 Mn |
| Dec 31, 2020 | -1.39 Mn |
| Sep 30, 2020 | 1.20 Mn |
| Sep 30, 2020 | 1.20 Mn |
| Jun 30, 2020 | 115,982.00 |
| Jun 30, 2020 | 115,982.00 |
| Mar 31, 2020 | 500,000.00 |
| Mar 31, 2020 | 500,000.00 |
| Dec 31, 2019 | 500,000.00 |
| Dec 31, 2019 | 500,000.00 |
| Sep 30, 2019 | 854,315.00 |
| Sep 30, 2019 | 854,315.00 |
| Jun 30, 2019 | 760,355.00 |
| Jun 30, 2019 | 760,355.00 |
| Mar 31, 2019 | 12,000.00 |
| Mar 31, 2019 | 12,000.00 |
| Dec 31, 2018 | 200,000.00 |
| Dec 31, 2018 | 200,000.00 |
| Sep 30, 2018 | 71,525.00 |
| Sep 30, 2018 | 71,525.00 |
| Jun 30, 2018 | 793,287.00 |
| Jun 30, 2018 | 793,287.00 |
| Mar 31, 2018 | 16,609.00 |
| Mar 31, 2018 | 16,609.00 |
| Dec 31, 2017 | 1.97 Mn |
| Dec 31, 2017 | 1.97 Mn |